Transplantation of umbilical cord and bone marrow-derived mesenchymal stem cells in a patient with relapsing-remitting multiple sclerosis

Untitled

“…There is currently great interest in the use of mesenchymal stem cells as a therapy for multiple sclerosis with potential to both ameliorate inflammatory processes as well as improve regeneration and repair. 9,10 A previous study showed that intrathecally injected peripheral blood stem cells are safe for patients and could be as effective as the bone marrow-derived stem cells, 11 which also concurs with the results of our study. However, early clinical improvement (within 1-2 weeks) was seen in our study in reverse to this previous study 11 in which improvement began after 2 weeks.…”

Mesenchymal stem cells: Immunomodulatory capability and clinical potential in immune diseases

“…In addition, the results showed that patient MSCs exhibited phenotypic changes, distinct transcriptional profile and functional defects implicated in MSC immunomodulatory and immunosuppressive activity [164]. [167]. However, obviously lots of effective trials still will be needed before MSCs can be used for MS clinical treatment in future.…”

Nonviral Reprogramming Genes Accelerate Formation of Neurons from Murine Embryonic Brain Cells: Synergistic Effect of Brain Derived Neurotrophic Factor Gene Therapy

“…The reprogrammed stem cells present greatly promises to downstream clinical applications for restoring, maintaining, or enhancing tissue and organ function for neurodegenerative disorders, such as Parkinson's disease [1], Alzheimer's disease [35], multiple sclerosis [36], spinal cord injury [37], stroke [38], and possibly neuropsychiatric illnesses [4,26]. However, for real-world clinical transition there are concerns about technologies in quantities and quickness of neuron products, including differentiated progressive staging neuronal cells generated by reprogrammed stem cells, and potential cancer risks for viral vector carrying reprogramming genes.…”